Healthcare Industry News: osteoporosis
News Release - September 14, 2009
Lilly Names New Business LeadersINDIANAPOLIS, Sept. 14 (Healthcare Sales & Marketing Network) -- In conjunction with today's announcement of a new operating model to speed innovative medicines to patients, Eli Lilly and Company (NYSE: LLY ) has named the leaders of its Development Center of Excellence and its five business units: oncology, diabetes, established markets, emerging markets, and Elanco animal health. These leaders will provide improved line of sight to Lilly's customers. Each will carry clear decision-making authority and accountability for their respective parts of the business.
The new leaders are:
Tim Garnett, M.D., and Tom Verhoeven, Ph.D., will lead the Development Center of Excellence within Lilly Research Laboratories. Garnett will have responsibility for medical, regulatory, global product safety, translational medicine and global health outcomes. Verhoeven will have responsibility for the clinical development organization, product R&D, toxicology/ADME and project management.
John H. Johnson will lead the oncology business unit. Johnson currently serves as chief executive officer of ImClone Systems, a wholly-owned subsidiary of Lilly.
Enrique A. Conterno will lead the diabetes business unit. Conterno currently serves as president of Lilly USA, the company's U.S. business operations.
Bryce D. Carmine will lead the established markets business unit. Carmine currently serves as Lilly's executive vice president of global marketing and sales.
Jacques Tapiero will lead the emerging markets business unit. Tapiero currently serves as Lilly's president of the intercontinental region.
Jeffrey N. Simmons will lead Elanco, the animal health business unit, where he currently serves as president.
Appointments for each of the four pharmaceutical business unit leaders and the two leaders of the Development Center of Excellence will become effective on November 1, 2009.
"These are proven leaders who bring a wealth of experience and knowledge to their respective roles," said John C. Lechleiter, Ph.D., Lilly chairman, president and chief executive officer. "Each has demonstrated strong leadership and an ability to get results throughout their business careers. Moving forward, these individuals will play a critical role in the success of Lilly's new operating model."
Lechleiter also outlined the details of the Development Center of Excellence, while explaining the criteria used to establish Lilly's new business units:
- Development Center of Excellence - With over 60 molecules in clinical development, the Development Center of Excellence (COE) will be tasked with streamlining the development of pipeline molecules and speeding innovative medicines to patients. The ultimate goal of the Development COE is to accelerate the launch of important Lilly molecules over the next decade and bring innovative medicines to patients sooner.
- Oncology - With the acquisition of ImClone and the progression of its own pipeline, Lilly remains intent on building an oncology powerhouse. Currently, one-third of the company's pipeline is composed of molecules to treat various forms of cancer. The need for new and better treatments is staggering: the World Health Organization estimates 12 million cancer-related deaths per year by 2030.
- Diabetes - Lilly has long been a leader in diabetes care, with a dedicated asset base and a portfolio of commercially successful products and promising pipeline opportunities. The need for new and improved treatments for patients with diabetes is great: an estimated 246 million adults are affected worldwide. In addition, Lilly remains one of only a few global insulin suppliers.
- Established Markets - Lilly's other important therapeutic areas, including neuroscience, osteoporosis/bone and cardiovascular, are included in the established markets business unit. The established markets business unit will have geographic responsibility for these therapeutic areas in the United States, Japan, the European Union, Canada, and Australia / New Zealand. This business unit will also host Lilly's global marketing organization.
- Emerging Markets - The emerging markets business unit will include many of the world's fastest-growing markets, such as China, Russia, Brazil, Mexico, South Korea and Turkey. Lilly aims to increase its presence in these countries and others where strong growth rates for pharmaceuticals are projected over the next decade. The creation of an emerging markets business unit will increase the company's focus on these areas and best position Lilly to serve growing patient needs among two-thirds of the world's population.
- Elanco Animal Health - Lilly remains committed to its animal health business. Elanco sales continue to grow at a rate faster than the overall animal health market. Elanco is positioned to deliver double-digit earnings growth over the next five years, bolstered by several recent acquisitions and the launch of its companion animal business.
Dr. Tim Garnett is currently chief medical officer and senior vice president of global medical, regulatory and safety for Lilly. During his 11-year tenure at Lilly, Garnett has served as vice president for global patient safety; global brand development leader; as group medical director responsible for the development of duloxetine; and European clinical research physician for raloxifene.
Prior to joining Lilly, Garnett acquired seven years of experience, holding a variety of positions in the pharmaceutical industry in Europe with Organon Laboratories.
Garnett qualified in medicine at St. George's Hospital in London. He practiced obstetrics and gynecology for eight years prior to joining the pharmaceutical industry and conducted clinical research into menopause, premenstrual tension and postmenopausal osteoporosis. He is a fellow of the Royal College of Obstetricians and Gynecologists in the United Kingdom and a fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians. He is a member of the Royal Society of Medicine.
Thomas Verhoeven, Ph.D., joined Lilly as vice president for product research and development in June 2003 responsible for the chemical, bioproduct, analytical, pharmaceutical and devices operations. In 2008, he was promoted to senior vice president of global product development. His current responsibilities include management of the therapeutic area platform teams including neuroscience, diabetes and endocrine, osteoporosis, oncology, and CV/acute care. He also directs global clinical operations and health outcomes. This responsibility includes all of the Phase III development work required for presubmission of new products and the ongoing development work required to support life cycle plans for those products already marketed. Verhoeven is a member of the LRL policy committee, the portfolio management committee and the corporate operations committee. He is also chair of the product development committee.
Prior to joining Lilly, Verhoeven worked for Merck Research Laboratories for 23 years. Within Merck Research Laboratories, he was responsible for the process development and commercialization of multiple products across a range of therapeutic classes, global operations and strategic research planning.
Verhoeven received a bachelor of science degree in chemistry from the University of Michigan, a doctorate in organic chemistry from the University of Wisconsin, and an appointment as a National Institutes of Health (NIH) fellow at Stanford University.
John H. Johnson has served as chief executive officer of ImClone Systems since August 2007. He also served as a member of the company's board of directors until the company was acquired by Lilly in November 2008.
Prior to joining ImClone, Johnson served as company group chairman of Johnson & Johnson's Worldwide Biopharmaceuticals unit. In this executive role, he was responsible for the Johnson & Johnson Biotechnology, Immunology and Oncology commercial businesses, including Centocor, Inc., Ortho Biotech Products, L.P. and the Worldwide Strategic Marketing group. Earlier in his career, Johnson held roles of increasing responsibility in sales and sales management at Pfizer before joining Johnson & Johnson to help lead their entry into the anti-infectives business. He advanced through positions of increasing responsibility with Ortho-McNeil, including leading the commercial groups responsible for the development of sales, marketing and new product strategies of several of the company's flagship brands.
Johnson received a bachelor of science degree from East Stroudsburg University of Pennsylvania. He is also a member of the boards of BioNJ and Cempra Pharmaceuticals.
Enrique A. Conterno was promoted to president of Lilly USA in January 2009. He is a member of Lilly's operations committee and senior management council. Prior to his promotion, Conterno served as senior vice president of health care professional markets for Lilly USA.
Born in Lima, Peru, Conterno earned a master of business administration degree at Duke University in 1992. He earned his bachelor's degree in mechanical engineering from Case Western Reserve University in 1989.
Conterno joined Lilly as a sales representative in 1992. From 1993 to 1995, he held roles as a financial analyst, marketing associate, and business development manager. In 1996, Conterno became sales and marketing director for the Peru affiliate, and in 1998, he became the sales and marketing director for Lilly's affiliate in Brazil. In 2000, Conterno was named executive director of marketing for the intercontinental region and Japan. Conterno served as president and general manager for Lilly's operations in Mexico in 2003, and was named vice president of Lilly USA's neuroscience business unit in July 2006. He serves on the Board of Visitors of the Fuqua School of Business at Duke University.
Bryce D. Carmine was named executive vice president, global marketing and sales, in April 2008. Prior to this position, Carmine had been president, global product development, with responsibility for the development of the late-phase pipeline molecules at Lilly. Prior to assuming this position, Carmine had a series of leadership roles that related to overseeing late-phase development of molecules for multiple therapeutic areas. His current responsibilities include leadership of the global pharmaceutical marketing and sales organizations across Lilly. He is a member of the company's executive committee and operations committee.
Born in New Zealand, Carmine received a bachelor of science in biochemistry from Massey University in 1973. He joined Lilly in 1975 in New Zealand and subsequently held several marketing and management positions in New Zealand before moving in 1983 to the company's corporate headquarters in Indianapolis.
In 1986, he was named general manager of Daewoong-Lilly Pharmaceutical Company in South Korea, a joint venture between Lilly and Daewoong. He became managing director of Lilly operations in Australia in 1989. During his tenure in Australia, he was actively involved in the Australian Pharmaceutical Research and Manufacturers Association, holding the position of chairman from 1992 to 1995. Carmine then served as the president and general manager of Lilly Japan from 1995 to June 1999 before returning to Indianapolis.
Jacques Tapiero was named president of the intercontinental region for Lilly in November 2004. The intercontinental region comprises offices in Asia, Australia, Africa and Middle East countries, Canada, Latin America and Russia. He also is a member of the company's senior management council. Tapiero had been president and general manager of Lilly France since December 1999.
Born in Morocco, Tapiero is a Swiss citizen who in 1980 received a master of business administration degree from the Ecole Superieure de Commerce at Clermond Ferrand in France. In 1982, he obtained a second master of business administration degree at the American Graduate School of International Management in Glendale, Arizona.
Tapiero joined Lilly in 1983 as a financial analyst. He held several sales and finance positions in Indianapolis, France and Switzerland. He was named managing director of Lilly Sweden in 1993. From 1995 to 1999, Tapiero was president and general manager at Lilly Brazil. In late 1999, Tapiero was named president and general manager for Lilly France.
Tapiero is a member of the Thunderbird Global Council, a council of leading business executives who advise Thunderbird, the School of Global Management.
Jeff N. Simmons was named president of Elanco, the animal health division of Lilly, in January 2008.
Simmons received a bachelor's degree in agricultural economics and marketing from Cornell University in 1989. Simmons joined Lilly in 1989 in sales. He has held numerous positions over the last 19 years within Elanco, including executive director of global strategy, operations and research and development; area director, Western Europe, based in the United Kingdom; and country director for Brazil, located in Sao Paulo. He has managed Elanco's international marketing for cattle and poultry and has also held other marketing and sales management positions in Elanco's domestic and international areas.
Simmons is a leading spokesperson on the role of technology in the global food chain, as well as change leadership and execution in the agricultural and food industries. He is a member of the Animal Health Institute's executive committee and is chairman of its board of directors. He is also a member of Harvard's PAPSAC committee (Private and Public, Scientific, Academic, and Consumer Food Policy Council) and is chairman of the FFA Sponsors Board.
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.
Source: Eli Lilly
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsLilly Announces Start of a Phase 1 Study for its Second Potential COVID-19 Antibody Treatment
Lilly's Taltz(R) (ixekizumab) is the First IL-17A Antagonist to Receive U.S. FDA Approval for the Treatment of Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
Lilly Begins World's First Study of a Potential COVID-19 Antibody Treatment in Humans